HOMA-IR: difference between revisions
Diff·revision 16 → 17·14:42, 19 Jun 2025
Difference between revision 16 and revision 17 of HOMA-IR. 6 lines changed; the page grew by 755 bytes.
| Revision 16 — 13:07, 30 May 2025 LyophilLena (talk) fix hyphenation per PP:MOS 3,463 bytes +32 | Revision 17 — 14:42, 19 Jun 2025 CiteBot (talk) bot: normalise unit spacing 4,218 bytes +755 | ||
|---|---|---|---|
| 37 | For that reason it appears widely in epidemiology and rarely in individual clinical decision-making.{{r|matthews1985}} | 37 | For that reason it appears widely in epidemiology and rarely in individual clinical decision-making.{{r|matthews1985}} |
| 38 | 38 | ||
| + | 39 | == Behaviour under weight loss and incretin therapy == | |
| + | 40 | HOMA-IR falls with weight loss by any means, and the fall tracks the improvement in insulin sensitivity that accompanies reduced adiposity. This is a well-replicated finding and is not specific to any pharmacological class.{{r|drucker2018}} | |
| + | 41 | ||
| + | 42 | Under incretin therapy, both inputs move: insulin secretion is amplified while the drug is present, and sensitivity improves with weight loss. The resulting index change is therefore a composite, and attributing it to a change in sensitivity alone is unsound.{{r|wallace2004}} | |
| + | 43 | ||
| 39 | == References == | 44 | == References == |
| 40 | {{reflist}} | 45 | {{reflist}} |
| 41 | <ref name="matthews1985">Matthews DR, Hosker JP, Rudenski AS, et al. "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man." ''Diabetologia'' 28(7):412–419 (1985). PMID 3899825.</ref> | 46 | <ref name="matthews1985">Matthews DR, Hosker JP, Rudenski AS, et al. "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man." ''Diabetologia'' 28(7):412–419 (1985). PMID 3899825.</ref> |
| 42 | <ref name="wallace2004">Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling." ''Diabetes Care'' 27(6):1487–1495 (2004). PMID 15161807.</ref> | 47 | <ref name="wallace2004">Wallace TM, Levy JC, Matthews DR. "Use and abuse of HOMA modeling." ''Diabetes Care'' 27(6):1487–1495 (2004). PMID 15161807.</ref> |
| + | 48 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | |
| 43 | 49 | ||
| 44 | == See also == | 50 | == See also == |